Authors: Bryan Edgar Guevara MD , Elisa Rae Coo MD , Mary Jo Christine Bunagan MD
Abstract
Background: Turmeric demonstrated anti-inflammatory properties in laboratory and clinical studies that suggest its usefulness in psoriasis. This is the first randomized controlled trial comparing the efficacy and safety of turmeric 1% cream to clobetasol propionate 0.05% cream in the treatment of plaque-type psoriasis.
Objectives: To determine the efficacy and safety of turmeric 1% cream versus that of clobetasol propionate 0.05% cream in the treatment of plaque-type psoriasis.
Methods: This was a randomized, double-blind clinical trial to determine the proportion of patients with clinical remission. Secondary outcomes namely mean PASI and pruritus scores per visit, time to remission and incidence of adverse effects were also determined.
Results: Fifty-nine patients were randomized into two groups: a turmeric (n=30) and a clobetasol (n=29) group. After four weeks of treatment, there was no significant difference (p=0.36) in the proportions of patients with clinical remission in the turmeric group (5/20, 25%) and the clobetasol group (8/23, 35%) (RR 1.15, 95% CI 0.78-1.70). The average time to achieve clinical remission was 4 weeks in the turmeric group and 3.38 ± 1.06 weeks in the clobetasol group (p=0.07). There was no significant difference in post-treatment mean PASI scores in turmeric (8.77 ± 5.71) and clobetasol (7.26 ± 6.04) groups (p=0.40). Post-treatment mean pruritus scores in turmeric (6.9 ± 2.83) and clobetasol (5.83 ± 3.87) groups (p=0.30) were also statistically comparable. Two patients in the clobetasol group developed folliculitis.
Conclusion: Turmeric 1% cream demonstrated comparable efficacy and safety with clobetasol 0.05% cream in the treatment of mild to moderate plaque-type psoriasis.
Citation
Guevara BEK, Coo ER, Bunagan MJ. A randomized, double-blind clinical trial on the efficacy and safety of turmeric 1% cream in the treatment of plaque-type psoriasis in adults. J Phil Dermatol Soc 2019, 28(1), 23-32
Keywords
turmeric, psoriasis, herbal, Philippines
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.
Philippine Dermatological Society (PDS)- Health Information System. Most Common Skin Diseases, 2011.
Remadevi R, Surendran E, Kimura T. Turmeric in Traditional medicine. In Turmeric: the genus Curcuma. Ravindran PN, NirmalBabu K, Sivaraman K. Eds. CRC Press: Boca Raton, London,New York. 2007, pp. 409-436.
Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung B, Anand P. Potential of spice-derived phytochemicals for cancer prevention. Planta Med., 2008;74:1560-1569.
Funk JL, Frye JB, Oyarzo JN, Kuscuoglu N, Wilson J, McCaffrey G, et al. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum. 2006;54:3452-3464.
Heng MC, Song MK, Harker J, Heng MK. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol. 2000;143(5):937–949.
United States Food and Drug Agency (US FDA). http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.html
Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res. 2008;52(9):1010–1030.
Wen ZH, Xuan ML, Yan YH, Li XY, Yao DN, Li G et al. Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial. Trials. 2014; 15:294.
Long C, Finlay A, et al. The finger-tip unit–a new practical measure. Clinical and Experimental Dermatology. 1991;16(6):444-7.
Oakley, A. Psoriasis Area and Severity Index (PASI) score. 2011. Retrieved from http://www.dermnetnz.org/scaly/pasi.html
Tangtatco JA, Guillano V. A prospective, randomized, double-blind, comparative study on the efficacy and safety of capsaicin 0.05% cream versus clobetasol propionate 0.05% cream in the treatment of mild to moderate plaque type psoriasis. . 2014
Elman, S. et al. (2010). The 5-D itch scale: a new measure of pruritus. British Journal of Dermatology, 162. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875190/#!po=17.8571
Gupta S, Patchva S, Aggarwal B. Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J. 2013;15(1):195-218.
Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–4499.
Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D. 2008; 9(4):243–250.
Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63-7.
Szepietowski JC, Reich A, Wiśnicka B. Itching in patients suffering from psoriasis. Acta Dermatovenerologica Croatica. 2002;10(4):221–226.
Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. British Journal of Dermatology. 2000;143(5):969–973.
Szepietowski JC, Reich A. Pruritus in psoriasis: An update. European Journal of Pain, 2016. 20: 41–46.
Taneda K, Tominaga M, Negi O, Tengara S, Kamo A, Ogawa H, Takamori K. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol. 2011;165:277–284.
Zhao X, Xu Y, Zhao Q, Chen CR, Liu AM, Huang ZL. Curcumin exerts antinociceptive effects in a mouse model of neuropathic pain: descending monoamine system and opioid receptors are differentially involved. Neuropharmacology. 2012 Feb; 62(2):843-54.
Whim WS, Tak MH, Lee MH, Kim M, Kim M, Koo JY. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. The journal of Neurosicience. 2007;27(9):2331-2337.
Yeon KY, Kim SA, Kim MK, Ahn DK, Kim HJ, Jung SJ. Curcumin produces an antihyperalgesic effect via antagonism of TRPV1. J Dent Res. 2010. 89(2):170-4.
25. Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. J Invest Dermatol. 2015;135(11):2641.
More Articles
